CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab
Franziska Niehr, Wilko Weichert, Albrecht Stenzinger, Volker Budach, Ingeborg Tinhofer
Research output: Contribution to journal › Article › peer-review
11Scopus
citations
Fingerprint
Dive into the research topics of 'CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab'. Together they form a unique fingerprint.